Delving into the Latest Updates on [18F]3F-PHPG with Synapse

Overview

Basic Info

Drug Type

Small molecule drug, Diagnostic radiopharmaceuticals

Synonyms-

Target

NET

Action

modulators

Mechanism

SLC6A2 modulators(Norepinephrine transporter modulators)

Therapeutic Areas

NeoplasmsOther Diseases

Active Indication

PheochromocytomaNeoplasms

Inactive Indication-

Originator Organization

Rogel Cancer Center: University of Michigan

Active Organization

Sichuan University

Rogel Cancer Center: University of Michigan

Inactive Organization-

License Organization-

Drug Highest PhaseEarly Phase 1

First Approval Date-

Regulation-

Login to view timeline

The goal of this exploratory study is to test whether [18F]3F-PHPG can be used reliably to map the locations of tumors in patients with neuroendocrine tumors. If so, the results of this study will be used to support further development of [18F]3F-PHPG as a clinical tool for neuroendocrine tumor localization and staging.

Start Date19 Oct 2020

Sponsor / Collaborator

Rogel Cancer Center: University of Michigan

NCT02669563

/ CompletedEarly Phase 1IIT

An Exploratory Study of 18F-Labeled Hydroxyphenethylguanidines in Heart Failure Patients

The main goal of this study is to test two new radioactive drugs, 4-[18F]fluoro-meta-hydroxyphenethylguanidine ([18F]4F-MHPG) and 3-[18F]fluoro-para-hydroxyphenethylguanidine ([18F]3F-PHPG) in human subjects with congestive heart failure.
Evaluations of these imaging agents will include their uptake in heart, lungs and liver, their metabolic breakdown in blood, and their kinetics in the heart. Based on these studies, the better of the two drugs will be chosen for further studies in patients with heart disease. After the better compound is chosen, additional measures of its imaging properties, metabolism and pharmacokinetics will be done in subjects with heart failure.

Start Date01 Dec 2015

Sponsor / Collaborator

University of Michigan

NCT02385877

/ CompletedEarly Phase 1IIT

Clinical Translation of 18F-Labeled Hydroxyphenethylguanidines for Quantification of Regional Cardiac Sympathetic Nerve Density With PET

The purpose of this study is to perform first-in-human PET imaging studies of two new cardiac sympathetic nerve imaging agents, 4-[18F]fluoro-meta-hydroxyphenethylguanidine ([18F]4F-MHPG) and 3-[18F]fluoro-para-hydroxyphenethylguanidine ([18F]3F-PHPG).

Start Date01 Mar 2015

Sponsor / Collaborator

University of Michigan

100 Clinical Results associated with [18F]3F-PHPG

Login to view more data

100 Translational Medicine associated with [18F]3F-PHPG

Login to view more data

100 Patents (Medical) associated with [18F]3F-PHPG

Login to view more data

1

Literatures (Medical) associated with [18F]3F-PHPG

19 Dec 2025·JOURNAL OF ORGANIC CHEMISTRY

Automated Synthesis of NET-Targeted PET Tracers [ ¹⁸ F]4F-mHPG and [ ¹⁸ F]3F-pHPG through Photocatalyzed ¹⁸ F-Deoxyfluorination

Article

Author: Wu, Xiaoai ; Xie, Yang ; Wang, Yueqi ; Yin, Honghai ; Hu, Mingxing ; Chen, Wei ; Pan, Lili ; Cao, Yarong

The NET-targeted radiotracers [¹⁸F]4F-mHPG and [¹⁸F]3F-pHPG have demonstrated promising clinical applications; however, the preparation of these tracers remains challenging. Herein, we report an improved synthesis protocol that enables the efficient automated production of two PET tracers via photocatalyzed ¹⁸F-deoxyfluorination. [¹⁸F]4F-mHPG and [¹⁸F]3F-pHPG were prepared in excellent n.d.c. RCYs of 31.3 ± 0.4% and 22.4 ± 1% in only 1 h from readily available precursors, and further validated on the PC12 tumor model for head-to-head comparison.

100 Deals associated with [18F]3F-PHPG

Login to view more data